- Home
- CV vs ENGN Comparison
CV vs ENGN Comparison
Compare CV & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CV
- ENGN
- Stock Information
- Founded
- CV 2005
- ENGN 1999
- Country
- CV United States
- ENGN Canada
- Employees
- CV N/A
- ENGN N/A
- Industry
- CV
- ENGN
- Sector
- CV
- ENGN
- Exchange
- CV NYSE
- ENGN Nasdaq
- Market Cap
- CV 194.2M
- ENGN 191.1M
- IPO Year
- CV 2025
- ENGN N/A
- Fundamental
- Price
- CV $4.54
- ENGN $3.78
- Analyst Decision
- CV
- ENGN Buy
- Analyst Count
- CV 0
- ENGN 7
- Target Price
- CV N/A
- ENGN $23.29
- AVG Volume (30 Days)
- CV 1.0M
- ENGN 73.0K
- Earning Date
- CV 01-01-0001
- ENGN 09-09-2025
- Dividend Yield
- CV N/A
- ENGN N/A
- EPS Growth
- CV N/A
- ENGN N/A
- EPS
- CV N/A
- ENGN N/A
- Revenue
- CV $12,044,000.00
- ENGN N/A
- Revenue This Year
- CV N/A
- ENGN N/A
- Revenue Next Year
- CV N/A
- ENGN N/A
- P/E Ratio
- CV N/A
- ENGN N/A
- Revenue Growth
- CV 20.54
- ENGN N/A
- 52 Week Low
- CV $3.49
- ENGN $2.65
- 52 Week High
- CV $5.72
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- CV N/A
- ENGN 54.41
- Support Level
- CV N/A
- ENGN $3.25
- Resistance Level
- CV N/A
- ENGN $3.98
- Average True Range (ATR)
- CV 0.00
- ENGN 0.24
- MACD
- CV 0.00
- ENGN 0.02
- Stochastic Oscillator
- CV 0.00
- ENGN 63.95
About CV CAPSOVISION INC
CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.